$再生元制药(REGN)$ Bayer added on the call that they have their own goal for Eylea, to get the 8mg dose launched in “major territories” by 2024, noting the expiration date of the patent on the active ingredient, which is 2025 “in most of our markets.” Eylea is currently approved only at a 2mg dose to slow vision loss as a treatment for age-related macular degeneration, macular edema, and diabetic retinopathy.